Stockscreener 앱 받기
4.22
4.31%
-0.19
시간 외 거래:
4.19
-0.03
-0.71%
전일 마감가:
$4.41
열려 있는:
$4.2
하루 거래량:
1.85M
Relative Volume:
1.03
시가총액:
$589.38M
수익:
$7.83M
순이익/손실:
$-64.92M
주가수익비율:
-7.9668
EPS:
-0.5297
순현금흐름:
$-47.22M
1주 성능:
+1.20%
1개월 성능:
+19.89%
6개월 성능:
+76.57%
1년 성능:
+210.29%
1일 변동 폭
$4.08
$4.37
1주일 범위
$4.08
$4.56
52주 변동 폭
$1.16
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
Compare ACRS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.22 | 615.92M | 7.83M | -64.92M | -47.22M | -0.5297 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 개시 | Oppenheimer | Outperform |
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - Yahoo Finance
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Reports Positive ATI-052 Phase 1a Trial Results - TipRanks
Aclaris reports phase 1a trial results for ATI-052 antibody By Investing.com - Investing.com Canada
Aclaris Therapeutics announced that the Phase 1B clinical trial of its drug candidate ATI-052 is currently actively recruiting patients. - Bitget
Aclaris (NASDAQ: ACRS) touts ATI-052 data, targets lichen planus with ATI-2138 - Stock Titan
Aclaris targets lichen planus, a disease with no approved therapies - Stock Titan
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing - marketscreener.com
Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock - Investing.com
Aclaris Therapeutics (NASDAQ: ACRS) insider-linked fund sells 300,000 shares - Stock Titan
BML Investment lists 13.95M shares (9.9%) in Aclaris (NASDAQ: ACRS) - Stock Titan
Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday By Investing.com - Investing.com Canada
Aclaris Therapeutics to Announce Phase 1a Trial Results for ATI-052 and Lead Indication Selection for ATI-2138 on April 28, 2026 - Quiver Quantitative
What Aclaris will reveal Tuesday on two immune-disease drug programs - Stock Titan
Aclaris Therapeutics (ACRS) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - Sahm
Aclaris Therapeutics (ACRS) Proxy filing Summary - Quartr
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap DownHere's What Happened - MarketBeat
Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, board elections in Aclaris Therapeutics (NASDAQ: ACRS) 2026 proxy - Stock Titan
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Aclaris (ACRS) Stock Gap Down Watch (Investor Interest) 2026-04-20Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai
Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN
ACRS Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target - Moomoo
Oppenheimer initiates Aclaris stock with Outperform rating By Investing.com - Investing.com Australia
Oppenheimer initiates Aclaris stock with Outperform rating - Investing.com
H.C. Wainwright reiterates Aclaris stock rating on drug trial data By Investing.com - Investing.com Canada
Aclaris (ACRS) Stock: Momentum Shift (Marginal Gain) 2026-04-15Fast Rising Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming - Yahoo Finance
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4% - MarketBeat
Market Overview: What is the implied volatility of Aclaris Therapeutics Inc2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Is Aclaris (ACRS) Stock Attractive Now | Price at $4.00, Down 1.11%Turnaround Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Pullback Watch: Will Aclaris Therapeutics Inc benefit from AI trends2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
ACRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Sahm
Is Aclaris (ACRS) Stock Near a Bottom | Price at $3.98, Up 0.76%Price Surge - Xã Châu Thành
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance UK
Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts - National Today
RA Capital Group reports 7.63M Aclaris shares (NASDAQ: ACRS) - Stock Titan
Forecast Cut: Why is Aclaris Therapeutics Inc stock going upMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - MarketBeat
ACRS Stock Analysis: Aclaris Therapeutics Inc biotech stock gains 1.45 percent at 4.2 dollars - UBND thành phố Hải Phòng
Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
ACRS SEC FilingsAclaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.00%
자본화:
|
볼륨(24시간):